2021年3月22日 · Physicians may consider erenumab 140 mg as an option for migraine prevention in adults who have four or more migraine days a month The National Institute for Health and Care Excellence (NICE) has confirmed that erenumab can be prescribed for migraine prevention free of charge on the National Health Service (NHS) in England and Wales.

Erenumab was further investigated In May 2018, Aimovig (erenumab) became the first CGRP monoclonal antibody to be approved for the prevention of migraine in adults. Approval was supported by data including results of the Phase 3 STRIVE and ARISE studies in episodic migraine and the results of a large Phase 2 study in chronic migraine.

Our slide decks bring together extensive clinical trial data supporting the efficacy and safety of the CGRP monoclonal antibodies, erenumab, fremanezumab, galcanezumab and eptinezumab, and the CGRP receptor antagonists (gepants), ubrogepant, rimegepant and atogepant. Migraine care in Brazil: the role of anti-CGRP therapies is a new slide deck summarising clinical trial and real …

2021年4月27日 · The authors stress that this is class IV evidence but conclude that erenumab increased the probability of improved pain control in patients with medication resistant trigeminal neuralgia. Reference. Parascandolo E, Levinson K, Rizzoli P, Sharon R. Efficacy of Erenumab in the Treatment of Trigeminal Neuralgia: A Retrospective Case Series.

2020年11月2日 · Top line results from the Phase 4 HER-MES study of erenumab versus topiramate have demonstrated the superiority of erenumab in migraine prevention. Erenumab had a superior tolerability and efficacy profile compared to topiramate, with fewer discontinuations during the double-blind, 24-week treatment phase. Erenumab also showed superior efficacy, …

2021年2月11日 · However, when triptans were used as comparator, a signal of disproportionate reporting for spontaneous abortion was detected in association with erenumab, galcanezumab, and fremanezumab (reporting odds ratio 1.86, 95% confidence interval 1.12-3.13).

2023年11月20日 · ARISE evaluated the efficacy of erenumab 70 mg (as a subcutaneous monthly regimen) in patients with episodic migraine (defined as ≥ 4 to <15 migraine days per month with < 15 headache days per month). 5 The trial enrolled 577 patients: 286 to erenumab 70 mg and 291 to placebo. As in STRIVE, most patients were women (85%, mean age 42 years).

2020年11月19日 · Erenumab (AMG 334) Galcanezumab (LY2951742) Fremanezumab (TEV-48125) Eptinezumab (ALD403) Rimegepant (BHV-3000) Ubrogepant (MK-1602) Zavegepant (BHV-3500) Meeting Reports. 18th European Headache Congress 2024; 20th Migraine Trust International Symposium 2024; 10th European Academy of Neurology Congress 2024

Erenumab versus topiramate for the prevention of migraine – a randomised, double-blind, active-controlled phase 4 trial. Cephalalgia 2021 Nov 7. Online ahead of print. Fremanezumab. 8. Dodick DW, Silberstein SD, Bigal ME, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial

2020年1月22日 · In both the erenumab and galcanezumab studies, placebo effects were very small. A Phase 1 pharmacokinetics, safety and tolerability study has been published for fremanezumab 225 mg, 675 mg and 900 mg in Japanese and Caucasian healthy subjects. 2 This showed similar pharmacokinetic exposure parameters and safety measures for both groups …